Utama › Sindrom Bronkiolitis Obliterans › Florida
Kajian klinikal Sindrom Bronkiolitis Obliterans di Florida
14 kajian untuk Sindrom Bronkiolitis Obliterans sedang mencari peserta di lokasi di Florida.
Bandar di Florida
Teks kajian rasmi (Bahasa Inggeris)
Axatilimab for Sclerotic Chronic Graft-versus-Host Disease
- Moffitt Cancer Center, Tampa
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT07011810An Efficacy and Safety Study of DFL24498 in the Treatment of AKC
- Bowden Eye Associates - Southside Location, Jacksonville
- University of Miami, Miller School of Medicine, Bascom Palmer Eye Institute, Miami
Mengambil pesertaFasa 3
Umur 10 hingga 65 · Semua jantina · Dikemas kini 21 Sep 2026 · NCT07395232Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease
- Moffitt Cancer Center, Tampa
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Sep 2026 · NCT05996627A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
- Miami Cancer Institute, Miami
- Orlando Health Cancer Institute Downtown Orlando, Orlando
- Memorial Cancer Institute, Pembroke Pines
Mengambil pesertaFasa 3
Umur 12 ke atas · Semua jantina · Dikemas kini 15 Sep 2026 · NCT06585774A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)
- Adventhealth Pediatric Cellular Therapy and Blood and Marrow Transplant, Orlando
Mengambil pesertaFasa 2
Umur 2 hingga 17 · Semua jantina · Dikemas kini 15 Sep 2026 · NCT07124078Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease
- Mayo Clinic Jacksonville, Jacksonville
- AdventHealth Orlando, Orlando
- Moffit Cancer Center, Orlando
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT05919511Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy
- Univ of Miami - Sylvester Comprehensive Cancer Center, Miami
- Moffitt Cancer Center, Tampa
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Ogo 2026 · NCT06660355Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease
- University of Miami, Miami
Mengambil pesertaFasa 2
Umur 12 ke atas · Semua jantina · Dikemas kini 22 Jun 2026 · NCT06663722A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
- University of Miami, Miami
Mengambil pesertaFasa 2
Umur 2 ke atas · Semua jantina · Dikemas kini 16 Jun 2026 · NCT04710576A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
- University of Miami, Miami
- Moffitt Cancer Center, Tampa
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 20 Mei 2026 · NCT06615050Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System (NAVIGATE)
- University of South Florida, Tampa
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Mei 2026 · NCT06464926A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
- AdventHealth Orlando, Orlando
- Moffitt Cancer Center, Tampa
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Dis 2025 · NCT06619561Uncovering the Mechanism of Pain Relief by Peripheral Transcutaneous Magnetic Stimulation
- Ambulatory Care Center, Florida International University, Miami
Mengambil peserta
Umur 19 hingga 80 · Semua jantina · Dikemas kini 30 Sep 2025 · NCT07199361Freedom-1 Study for Chronic Knee Pain
- Holy Cross Hospital, Inc, Fort Lauderdale
- Florida Joint Care Institute, Trinity
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 13 Feb 2025 · NCT03877653Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.